Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04028063
Recruitment Status : Not yet recruiting
First Posted : July 22, 2019
Last Update Posted : November 19, 2019
National Cancer Institute (NCI)
Agenus Inc.
Information provided by (Responsible Party):
University of Colorado, Denver

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : November 24, 2021
Estimated Study Completion Date : November 2022